沙利度胺治疗小肠血管发育不良所致消化道出血的疗效观察

The therapeutic effect of thalidomide on small intestinal bleeding caused by angiodysplasia: an observational study

目的观察沙利度胺治疗小肠血管发育不良所致消化道出血的临床疗效。方法收集2009年1月．2011年10月小肠血管发育不良所致消化道出血患者20例，给予沙利度胺片100mg／d口服，疗程4个月，观察治疗前、后患者临床疗效。结果患者临床疗效总评分由治疗前的（14．56±3．30）分降至治疗后的（5．23±3．25）分，差异有统计学意义（P〈0．01）。随访期间，20例患者平均出血次数为（1．00±1．13）次，输血量为（100．00±230．01）mL，均比治疗前显著减少[（11．12±5．73）次和（1338．22±1451．32）mL，P值均〈0．01）；治疗后血红蛋白含量为（9．41±2．17）g／mL，比治疗前的（5．68±1．60]g／mL）显著上升（P〈O．01]。结论沙利度胺对小肠血管发育不良所致的消化道出血疗效显著，可望成为一种治疗小肠血管发育不良的有效药物。

Objective To observe the therapeutic effect of thalidomide on small intestinal bleeding caused by angiodysplasia. Methods Twenty patients with recurrent small intestinal bleeding caused by an- giodysplasia were treated with thalidomide 100 mg daily for 4 months. Follow-up time was 12 months. The change of clinical setting between pre-therapy and post-therapy was compared. Results The clinical setting of patients in post therapy was significantly better than that in pre-therapy. The overall symptom score, the medi- an bleeding frequency and median transfusion volume in patients after therapy was significantly lower than those before the therapy （14.56 ± 3.30） vs （5.23 ± 3.25）, （11.12± 5.73）vs （1.00 ±1.13）, （1338.22 ± 1451.32） mL vs （100.00 ± 230.01 ）mL, respectively, （all P 〈 0.01）, while median hemoglobin was obviously higher than that before the therapy（5.68± 1.60）g/mL vs （9.41 ± 2.17）g/mL （P 〈 0.01）. Conclusions Thalidomide is effec- tive in treating small intestinal bleeding caused by angiodysplasia.